Using the TPT technology, an injection called VGV-L has been developed to treat Lyme disease, an illness that saw a 100% increase in CDC-confirmed cases from 1991 to 2006. Animal studies have been completed with positive results. We have completed a pre-IND meeting with the FDA for a proposed clinical development program, including a clinical trial.
The early research in this area was supported by grants from two not-for-profit organizations that saw the promise in our approach helping enable the Company to reach this phase of development. The proposed therapy, like several others in our R&D pipeline, is based on TPT and uses synthetic peptides to render pro-inflammatory cells vulnerable to the body’s natural containment protocols
http://www.vglifesciences.com/development/#developmental-studies